A new pill called daraxonrasib stopped cancer from growing in nearly 90% of patients with advanced pancreatic cancer in a major clinical trial.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Breakthrough Targeted Therapy Shows Promise for KRAS‑Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role
90 % Disease control rate
Daraxonrasib Drug name
New England Journal Of Medicine Published in
KRAS-Mutated Pancreatic Cancer Cancer type treated
3 Phase trials completed